Rosetta Genomics Ltd. (NASDAQ:ROSG) released its quarterly earnings data on Monday. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.01. The company had revenue of $2.40 million for the quarter.
Rosetta Genomics (NASDAQ:ROSG) opened at 0.88 on Wednesday. Rosetta Genomics has a 1-year low of $0.71 and a 1-year high of $2.68. The company’s market cap is $18.35 million. The stock has a 50 day moving average of $0.97 and a 200-day moving average of $1.12.
ROSG has been the topic of a number of recent research reports. S&P Equity Research decreased their price objective on Rosetta Genomics from $0.94 to $0.82 in a report on Wednesday, September 7th. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Rosetta Genomics in a report on Monday, June 13th.
Rosetta Genomics Company Profile
Rosetta Genomics Ltd. is engaged in developing and commercializing new diagnostic tests based on various genomics markers, including deoxyribonucleic acid (DNA), micro ribonucleic acid (microRNA) and protein biomarkers and using various technologies, including, Quantitative polymerase chain reaction (qPCR), microarrays, Next Generation Sequencing (NGS) and Fluorescence In Situ Hybridization (FISH).
Receive News & Ratings for Rosetta Genomics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rosetta Genomics Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.